Resonant

Exciting news this month: the FDA has approved Eli Lilly and Company’s new treatment for early-stage Alzheimer’s disease, Kisunla (donanemab-azbt). This groundbreaking therapy targets the clearance of amyloid plaques, clumps of toxic proteins that are characteristic of Alzheimer's-diseased brains. With a unique limited-duration regimen, Kisunla was shown to slow cognitive and functional decline and reduce amyloid plaques with approximately 12 months of treatment. This milestone marks a significant step forward in developing therapies to combat Alzheimer's disease. Resonant remains dedicated to developing tests for detecting early biomarkers of Alzheimer's disease-related neurodegeneration and supporting the development of effective therapies. To visit the official announcement: https://lnkd.in/g5r922fT. To learn more about Resonant's mission, visit: www.resonantdx.com #AlzheimersDisease #Dementia #BrainHealth #NeurodegenerativeDisease #HealthyAging #EndAlz

"Liquid biopsy is poised to redefine the way we approach diagnostics and personalized medicine in the treatment of complex diseases." Resonant's co-founder, Tim Jenkins, contributed to Front Line Genomics' special report on Liquid Biopsies, tests performed on blood or other body fluids to understand disease. He discusses how liquid biopsies can be used to detect neurodegenerative disorders and how our developing test for Alzheimer's disease may eventually be used for identifying the disease before symptoms appear. #liquidbiopsy #alzheimersdisease #alzheimers #neurodegenerativedisease #diagnostics #precisionmedicine #personalizedmedicine #endalz https://lnkd.in/eaeb7c-e

Resonant supports Rare Disease Day! Did you know that approximately 1 in 10 people in the US are affected by rare disease? Because funding and patients are limited in rare diseases, studying and developing diagnostics and treatments is incredibly challenging. But because aproximately 80% of rare diseases have a genetic basis, advancements in DNA sequencing technologies in recent decades are revolutionizing diagnoses and improving therapeutics for many conditions. We are extremely optimistic this trend will continue—to ensure a brighter future for those living with rare disease! For the most up-to-date information about genetic and rare diseases, visit the National Institutes of Health's Genetic and Rare Disease Information Center at: https://lnkd.in/gQvEfy5t #rarediseaseday2024 #rarediseases #neurodegenerativediseases #als #alsawareness #diagnostics

"Liquid biopsy is poised to redefine the way we approach diagnostics and personalized medicine in the treatment of complex diseases." Resonant's co-founder, Tim Jenkins, contributed to Front Line Genomics' special report on Liquid Biopsies, tests performed on blood or other body fluids to understand disease. He discusses how liquid biopsies can be used to detect neurodegenerative disorders and how our developing test for Alzheimer's disease may eventually be used for identifying the disease before symptoms appear. #liquidbiopsy #alzheimersdisease #alzheimers #neurodegenerativedisease #diagnostics #precisionmedicine #personalizedmedicine #endalz https://lnkd.in/eaeb7c-e

"Today's dementia research investments are tomorrow's breakthroughs." 2023 was a landmark year for the Alzheimer's Association®, the world's largest nonprofit funder of Alzheimer's research. The organization invested $100 million in Alzheimer's research initiatives, making 2023 the largest single year investment since the Alzheimer's Association's founding. Over the last decade, the Alzheimer's Association has seen an increase in diversity of the projects being funded—research exploring alternative mechanisms of the disease and different approaches to treatment and disease management. Resonant is working on developing early diagnostic tools, hopeful that the combination of early diagnostics with more comprehensive treatment options will make a significant impact on those affected by Alzheimer's. #alzheimersdisease #research #AlzheimersAssociation #endalz https://lnkd.in/g7akA7jx

Open science initiatives that harness human genomic and genetic data for research, such as the Alzheimer's Disease Data Initiative or the National Institute of Health's Gene Expression Omnibus repository, are enhancing the development of drugs and diagnostics for neurodegenerative diseases. These initiatives collect patient clinical and multi-omics data to help researchers understand variation in the clinical manifestations of neurodegenerative diseases (NGD), discover biomarkers, and identify potential targets for drug development. These resources have been essential to Resonant's research and have helped shape the development of our diagnostic tests for Alzheimer's and other neurodegenerative disorders. Read more about Resonant's groundbreaking Alzheimer's research at: https://lnkd.in/gQRsAUfF #genomics #epigenetics #dna #sequencing #multiomics #alzheimersdisease #neurodegenerativedisease #diagnostics #endalz

"Today's dementia research investments are tomorrow's breakthroughs." 2023 was a landmark year for the Alzheimer's Association®, the world's largest nonprofit funder of Alzheimer's research. The organization invested $100 million in Alzheimer's research initiatives, making 2023 the largest single year investment since the Alzheimer's Association's founding. Over the last decade, the Alzheimer's Association has seen an increase in diversity of the projects being funded—research exploring alternative mechanisms of the disease and different approaches to treatment and disease management. Resonant is working on developing early diagnostic tools, hopeful that the combination of early diagnostics with more comprehensive treatment options will make a significant impact on those affected by Alzheimer's. #alzheimersdisease #research #AlzheimersAssociation #endalz https://lnkd.in/g7akA7jx

Early detection of Alzheimer's disease could not only give patients earlier access to treatments and allow them to better prioritize their health and plan for the future, but could also save $7 trillion in associated US healthcare costs. #alzheimersdisease #endalz #earlydetection #whygetchecked https://lnkd.in/dJ_Y3w3

Despite significant progress in the field of neurodegenerative disease (NGD), researchers believe a comprehensive biomarker panel could not only accelerate research and the development of new treatments, but also offer tools for more effective disease monitoring and management. Resonant is currently working on filling this gap, developing tests for Alzheimer’s disease, Parkinson’s disease, ALS, and other neurodegenerative conditions with the ultimate goal of creating a more comprehensive NGD panel. Visit resonantdx.com to join our waitlist or receive updates on our developing technology. #neurodegenerativedisease #diagnostics #epigenetics #diseaseprevention #brainhealth

Joseph Antoun, M.D., PhD, a longevity expert and CEO of the nutrition tech company Prolon in Los Angeles comments on our recently published research! "This method of measuring DNA methylation shows interesting potential," Antoun told Fox News Digital. Our research team is currently working on other studies to validate our technology for Alzheimer’s disease and other neurodegenerative conditions such as Parkinson’s disease, amyotrophic lateral sclerosis (Lou Gehrig’s disease), and others. #alzheimersdisease #neurodegenerativediseases #diagnostics #endalz https://lnkd.in/gCUbc9k4